Wei Liu

Counsel

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

pdf

Wei Liu is counsel in O'Melveny's Beijing office. His major practice area is capital markets, including IPOs, pre-IPO investments, secondary offerings, M&A, general corporate matters, and compliance.

Languages

  • English
  • Mandarin

Admissions

  • New York

Education

  • Peking University, LL.B.; LL.M.
  • Southern Methodist University Dedman School of Law, LL.M., Sohmen Scholar

Professional Activities

Bar Exam

  • Passed Chinese Bar Exam

Initial Public Offerings

  • Yonghe Medical Group Co., Ltd. in its US$206 million IPO and listing on the Hong Kong Stock Exchange
  • Acotec Scientific Holdings Limited in its US$210 million IPO and listing on the Hong Kong Stock Exchange
  • Fortune Capital, CICC and other underwriters in the US$56.80 million IPO and listing of Zero2IPO Holdings Inc. on the Hong Kong Stock Exchange
  • JACOBIO Pharmaceuticals Group Co., Ltd. in its US$174 million IPO and listing on the Hong Kong Stock Exchange
  • J.P. Morgan, BofA Securities, CICC, Haitong and other underwriters in the US$1.67 billion secondary listing of GDS Holdings Limited on the Hong Kong Stock Exchange
  • CCBI, CICC, CMBI and other underwriters in the US$420 million IPO and listing of Jinshang Bank Co., Ltd. on the Hong Kong Stock Exchange
  • China Feihe Limited in its US$856 million IPO and listing on the Hong Kong Stock Exchange
  • China Tower Corporation Limited in its US$6.9 billion IPO and listing on the Hong Kong Stock Exchange
  • CLSA, J.P. Morgan and other underwriters in the US$217 million IPO and listing of Huifu Payment Limited on the Hong Kong Stock Exchange
  • BAML, CICC, CCBI, Goldman Sachs and other underwriters in the US$1.8 billion IPO and listing of China Resources Pharmaceutical Group Limited on the Hong Kong Stock Exchange
  • CICC, Goldman Sachs, ABCI and other underwriters in the US$811 million IPO and listing of China International Capital Corporation Limited on the Hong Kong Stock Exchange
  • CMS and other underwriters in the US$215 million IPO and listing of Yunnan Water Investment Co., Limited on the Hong Kong Stock Exchange
  • BAML, Credit Suisse and other underwriters in the US$146 million IPO and listing of Xiabuxiabu Catering Management (China) Holdings Co., Ltd. on the Hong Kong Stock Exchange
  • J.P. Morgan, Guotai Junan and other underwriters in the US$70 million IPO and listing of Sunfonda Group Holdings Limited on the Hong Kong Stock Exchange
  • BAML, Credit Suisse, Goldman Sachs, Morgan Stanley, UBS and other underwriters in the US$2.5 billion IPO and listing of China Cinda Asset Management Co., Ltd. on the Hong Kong Stock Exchange
  • China Everbright Bank Company Limited in its US$3.0 billion IPO and listing on the Hong Kong Stock Exchange
  • CICC, BOCI, BNP Paribas, UBS, BAML, Macquarie and other underwriters in the US$902 million IPO and listing of Inner Mongolia Yitai Coal Co., Ltd. on the Hong Kong Stock Exchange

Secondary Offerings

  • China CITIC Bank in its US$4 billion A + H share rights issue
  • PICC Property & Casualty in its US$1.17 billion / US$938 million domestic + H share rights issue
  • China Communications Services in its US$472 million domestic + H share rights issue
  • Beijing Jingneng Clean Energy in its US$119 million H share placement

Mergers & Acquisitions

  • Viva Biotech in its US$387.3 million acquisition of Langhua Pharmaceutical and US$135.4 million share placement
  • China Zhongwang in its proposed spin-off of its industrial aluminium extrusion business by disposing all the equity interest in Liaoning Zhongwang Group to CRED Holdings
  • China Zhongwang in its proposed acquisition of Aleris Corporation in the United States